



CASES

INSIGHTS INTO OVARIAN CANCER


Thursday, December 17, 2020

Northwest Region

HOW TO NAVIGATE THIS REPORT



Click to move to topic of interest or ARS supporting data



Click to return to previous slide

Topic
Study Objective 
Report Snapshot 
Participant Demographics 
Key Insights 
Advisor Key Takeaways 
ARS Data – Molecular Testing in Advanced Ovarian Cancer 
ARS Data – First-Line and Maintenance Therapy Options 

STUDY OBJECTIVE



- > To gain advisors' perspectives on the management of ovarian cancer with regard to molecular testing and first-line and maintenance therapy options

- > A moderated, virtual roundtable discussion focusing on treatment of ovarian cancer was held on December 17, 2020
- > Disease state and data presentations were developed in conjunction with Dr Dan Veljovich from Swedish Cancer Institute
- > Insights on the following therapies were obtained: chemotherapies (platinums, taxanes), olaparib, niraparib, bevacizumab
- > Data collection was accomplished through use of audience response system (ARS) questioning and in-depth moderated discussion

REPORT SNAPSHOT (2/2)



> The group of advisors comprised 8 community oncologists from several practices

Practice	City/State	# of Advisors
Swedish Cancer Institute	Seattle, WA	1
Rocky Mountain Oncology	Casper, WY	1
Sutter Medical Group	San Francisco, CA	1
Washington Permanente Medical Group	Tacoma, Silverdale, WA	1
Kadlec Clinic of Hematology & Oncology	Kennewick, WA	1
Enloe Specialty Physicians	Chico, CA	1
San Jose Medical Group	San Jose, CA	1
EPIC CARE	Emeryville, CA	1




CASES

Participant Demographics



PARTICIPANT DEMOGRAPHICS (1/2)



PARTICIPANT DEMOGRAPHICS (2/2)

What percentage of your TOTAL patients whom you see per month have gynecologic cancers? (N = 7*)

What proportion of your gynecologic cancer patients whom you see per month have ovarian cancer? (N = 7*)

FOR EXAMPLE PURPOSES ONLY



CASES

Key Insights

Molecular Testing in Advanced Ovarian Cancer

[Redacted content]

[Redacted content]

MOLECULAR TESTING IN ADVANCED OVARIAN CANCER – QUOTES



“What I'm looking for is a test that's coherent, that gives me an

[Blurred text block]


[Blurred text block]

FIRST-LINE AND MAINTENANCE THERAPY OPTIONS (1/2)



Topic	Data and Insights
-------	-------------------

Perceptions of	Advisors showed a preference to use olaparib in <i>BRCA</i> -mutated patients, for a wide variety of reasons. SOLO-1 is
----------------	---



FIRST-LINE AND MAINTENANCE THERAPY OPTIONS (2/2)



Topic	Data and Insights
Patient case	For <i>BRCA</i> -mutated patients, carboplatin-paclitaxel is the preferred primary treatment, and olaparib is the strongly

FIRST-LINE AND MAINTENANCE THERAPY OPTIONS – QUOTES



“For the mutant [*BRCA*-mutated disease], I use either one . . . olaparib or

“Frontline. Like olaparib better because . . . SOL14 is deep in

[blurred text]



Advisor Key Takeaways

ADVISOR KEY TAKEAWAYS



Dr 1

- Importance of upfront HRD testing

[Blurred content for Dr 1]

Dr 2

- Consideration of Myriad testing

[Blurred content for Dr 2]



CASES

ARS DATA

MOLECULAR TESTING IN ADVANCED
OVARIAN CANCER

WHAT PERCENTAGE OF YOUR FIRST-LINE OVARIAN CANCER PATIENTS RECEIVE GERMLINE *BRCA* MUTATION TESTING? (N = 7*)

FOR EXAMPLE PURPOSES ONLY

WHAT PERCENTAGE OF YOUR FIRST-LINE OVARIAN CANCER PATIENTS RECEIVE TUMOR (SOMATIC *BRCA*) TESTING? (N = 7*)

FOR EXAMPLE PURPOSES ONLY

ARE YOU TESTING FOR HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) IN THE FRONTLINE TO INFORM TREATMENT DECISIONS? (N = 7*)

FOR EXAMPLE PURPOSES ONLY

WHICH OF THE FOLLOWING SAMPLE TYPES ARE YOU USING FOR HRD TESTING? PLEASE SELECT ALL THAT APPLY.



(N = 7*)

FOR EXAMPLE PURPOSES ONLY

DOES YOUR HRD TEST INCLUDE HOMOLOGOUS RECOMBINATION REPAIR (HRR) MUTATIONS AND GENOMIC INSTABILITY VIA TUMOR TISSUE? (N = 6*)

FOR EXAMPLE PURPOSES ONLY

*Two advisors did not answer question.

WHICH COMMERCIALY AVAILABLE GENE ASSAYS DO YOU CURRENTLY USE FOR HRRm TESTING? PLEASE SELECT ALL THAT APPLY. (N = 7*)

FOR EXAMPLE PURPOSES ONLY

*One advisor did not answer question.



CASES

ARS DATA

FIRST-LINE AND MAINTENANCE
THERAPY OPTIONS

APPROXIMATELY HOW MANY OVARIAN CANCER PATIENTS HAVE YOU TREATED WITH NIRAPARIB (ZEJULA) OVER THE PAST 3 MONTHS? (N = 7*)

FOR EXAMPLE PURPOSES ONLY

*One advisor did not answer question.

APPROXIMATELY HOW MANY OVARIAN CANCER PATIENTS HAVE YOU TREATED WITH OLAPARIB (LYNPARZA) OVER THE PAST 3 MONTHS? (N = 8)

CASES

FOR EXAMPLE PURPOSES ONLY

WHICH OF THE FOLLOWING PARPi HAS THE MOST FAVORABLE SAFETY PROFILE IN OVARIAN CANCER? (N = 7*)

CASES

FOR EXAMPLE PURPOSES ONLY

*One advisor did not answer question.



WHICH RECENT APPROVAL FOR PRIMARY MAINTENANCE HAS HAD THE BIGGEST IMPACT ON YOUR PRACTICE?

FOR EXAMPLE PURPOSES ONLY

WHAT DO YOU ANTICIPATE BEING YOUR MOST COMMONLY USED APPROACH TO FIRST-LINE MAINTENANCE IN YOUR PATIENTS WITH NEWLY DIAGNOSED *BRCAm* ADVANCED

FOR EXAMPLE PURPOSES ONLY

WHAT DO YOU ANTICIPATE BEING YOUR MOST COMMONLY USED APPROACH TO FIRST-LINE MAINTENANCE IN YOUR PATIENTS WITH NEWLY DIAGNOSED HRD-POSITIVE/*BRCA*wt

FOR EXAMPLE PURPOSES ONLY

WHAT DO YOU ANTICIPATE BEING YOUR MOST COMMONLY USED APPROACH TO FIRST-LINE MAINTENANCE IN YOUR PATIENTS WITH NEWLY DIAGNOSED HRD-NEGATIVE/*BRC*Awt

FOR EXAMPLE PURPOSES ONLY

> 54 y/o with stage IIIC epithelial ovarian cancer s/p primary optimal debulking

• [Blurred text]

WHAT ADDITIONAL TESTING DO YOU ORDER? (N = 8)

FOR EXAMPLE PURPOSES ONLY

GERMLINE TESTING REVEALED A gBRCA MUTATION. WHAT THERAPY WOULD YOU RECOMMEND FOR PRIMARY TRFATMFNT? (N = 8)

FOR EXAMPLE PURPOSES ONLY

PATIENT CASE CONTINUED

> 54 y/o with stage IIIC epithelial ovarian cancer s/p optimal debulking surgery

• [Blurred text]

WHAT POSTTREATMENT STRATEGY WOULD YOU RECOMMEND? (N = 8)

FOR EXAMPLE PURPOSES ONLY

ASSUME THE PATIENT WITH A gBRCA MUTATION WAS GIVEN CARBOPLATIN-PACLITAXEL-BEVACIZUMAB AS PRIMARY THERAPY. WHAT WOULD YOU OFFER NOW AS

FOR EXAMPLE PURPOSES ONLY

IF THIS PATIENT WAS *BRCA1/2*wt AND HRP, WHAT WOULD YOU OFFER AS MAINTENANCE THERAPY AFTER CARBOPLATIN-PACLITAXEL-BEVACIZUMAB PRIMARY

FOR EXAMPLE PURPOSES ONLY

WHAT IS THE PRIMARY REASON YOU MIGHT CHOOSE PARP INHIBITOR MONOTHERAPY OVER BEVACIZUMAB + OLAPARIB FOR A PATIENT WITH A gBRCA1/2 MUTATION WHO

FOR EXAMPLE PURPOSES ONLY